Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck & Co/Schering-Plough merger to target international growth

This article was originally published in Scrip

Executive Summary

One of the driving forces behind the proposed merger of Merck & Co and Schering-Plough is the wish to create an entity that is stronger in international markets and has the potential to really exploit its opportunities there. The move is a bold step for Merck, which until now has avoided taking part in large M&A activity, even when many of its counterparts reshaped dramatically through M&A and overtook it in terms of critical mass and R&D capability.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC000670

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel